Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pump suspension Clear all

Conditions: Seasonal Allergic Rhinitis
Interventions: Mometasone Furoate Nasal Spray, 50 mcg, Nasonex Nasal Spray, 50 mcg, Placebo Nasal Spray; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 811 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 10
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Predictive Low Glucose Suspend Algorithm ON, Predictive Low Glucose Suspend Algorithm OFF; Device
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 46 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Stanford, California • Aurora, Colorado

Conditions: Pharmacokinetics, Bioavailability
Interventions: Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Advanced Parkinson's Disease
Interventions: Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube; Drug · Device
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 30 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Liver Diseases, Portal Hypertension
Interventions: SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Pump suspension algorithm; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 3 Years to 14 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Stanford, California • Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: interoperable Artificial Pancreas System (iAPS), Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS); Device · Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Santa Barbara, California • Stanford, California • Boston, Massachusetts + 2 more

Conditions: Analgesia
Interventions: Bupivacaine liposome injectable suspension, Bupivacaine HCl without epinephrine via continuous infusion; Drug
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Osteoporosis, Hypomagnesemia
Interventions: EffCaMgCit, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Erectile Dysfunction
Interventions: ASP-001.1, ASP-001, Commercial Sildenafil and Sildenafil/Tadalafil Products; Device · Drug
Lead sponsor: Aspargo Labs, Inc; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Bowel Obstruction
Interventions: IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension); Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Riverdale, Georgia

Conditions: Type 1 Diabetes
Interventions: Computer algorithm to initiate pump suspension; Device
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 25 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Volunteer
Interventions: GSK1349572, Placebo, Omeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine
Interventions: B244, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 313 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Little Rock, Arkansas • Long Beach, California • Riverside, California + 19 more

Conditions: Erectile Dysfunction
Interventions: ASP-001.1, ASP-001.1; Drug · Device
Lead sponsor: Aspargo Labs, Inc; Industry
Eligibility: 20 Years to 70 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Surgery, TAP Blocks
Interventions: Exparel, Ropivacaine; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 90 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Automatic closed-loop insulin delivery, Control; Device
Lead sponsor: Stanford University; Other
Eligibility: 14 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 3
States / cities: Angelus Oaks, California • Mountain View, California • Palo Alto, California

Conditions: Lower Limb Amputation
Interventions: Prosthetic Suction or Pin Socket, Prosthetic LimbLogic Vacuum Socket; Device
Lead sponsor: Ohio Willow Wood; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Columbus, Ohio • Mount Sterling, Ohio

Conditions: Osteoporosis, Hypomagnesemia
Interventions: EffCaMgCit, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Clostridium Difficile Infection
Interventions: Omeprazole (suspension), Lifestyle Modification; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 0 Years to 4 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes
Interventions: iAPS, Sensor-Augmented Pump; Device · Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Santa Barbara, California • Rochester, Minnesota

Conditions: Type 1 Diabetes
Interventions: Pump suspension; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 15 Years to 45 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Stanford, California • Aurora, Colorado

Conditions: Retraction of Colostomy
Interventions: IV morphine sulfate or Sponsor-approved equivalent, EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 3
States / cities: Tucson, Arizona • Orlando, Florida • Tampa, Florida

Conditions: Type1diabetes
Interventions: Artificial Pancreas Controller in Dual Hormone Mode, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode, XeriSol glucagon; Device · Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children

The International Diabetes Closed Loop (iDCL) Trial: Protocol 4

Extended Delivery of Bupivacaine Study in Herniorrhaphy

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

Adult Patients Undergoing Open Colectomy MA402S23B303

Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects

TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery

Assessment of an Automatic Closed-loop Insulin Delivery System

Evaluation of Limb Health Associated With a Prosthetic Vacuum Socket System

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

Effect of Acid Suppression Medication on Pediatric Microbiome

Artificial Pancreas With Different Stress Assessments in the Outpatient Setting

Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504

Three Way Crossover Closed Loop Study With Xeris Glucagon